KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Work In Process (2023 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Work In Process for 3 consecutive years, with $42.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Work In Process changed N/A year-over-year to $42.6 million, compared with a TTM value of $42.6 million through Sep 2025, changed N/A, and an annual FY2024 reading of $36.6 million, down 2.01% over the prior year.
  • Work In Process was $42.6 million for Q3 2025 at Aurinia Pharmaceuticals, down from $43.2 million in the prior quarter.
  • Across five years, Work In Process topped out at $43.2 million in Q2 2025 and bottomed at $36.6 million in Q4 2024.
  • Average Work In Process over 3 years is $40.3 million, with a median of $41.7 million recorded in 2025.
  • Peak annual rise in Work In Process hit 2.01% in 2024, while the deepest fall reached 2.01% in 2024.
  • Year by year, Work In Process stood at $37.4 million in 2023, then fell by 2.01% to $36.6 million in 2024, then rose by 16.42% to $42.6 million in 2025.
  • Business Quant data shows Work In Process for AUPH at $42.6 million in Q3 2025, $43.2 million in Q2 2025, and $41.7 million in Q1 2025.